Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...

A biotechnology company developing novel gene editing technologies and cell therapies focused on rare genetic diseases through innovative CRISPR-based platforms. A biotechnology company developing ...

Antibody drug conjugates bring a targeted approach to the treatment of many types of cancer, but there’s still room for improving this class of therapies. This week, two startups revealed how they aim ...

Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s ...

US biotech Stipple Bio has emerged from stealth with a $100 million series A, aiming to refine antibody-drug conjugates by targeting cancer cells at the epitope level rather than relying on payload or ...

Newly uncloaked Stipple Bio is connecting the dots toward multiple early-stage clinical studies for its lead precision oncology asset, buoyed by a $100 million series A financing round. The “heavily ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A ...

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE)-- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the close ...

- Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CEO Jeff Landau said the $100 ...